Doximity Stock Pick for the Healthcare Innovation Portfolio
Selected stock: Doximity, Inc. (NYSE: DOCS), the U.S. digital platform for medical professionals and clinician workflow tools.
Doximity is the strongest risk-adjusted healthcare technology pick for this global thematic portfolio because it combines real AI healthcare adoption with unusual profitability, high free cash flow, and a balance sheet that gives management flexibility. The market appears to be pricing DOCS as a slow-growth healthcare advertising platform, while the investment case is increasingly tied to workflow, clinical AI, scheduling, telehealth, prescribing and productivity tools used by clinicians.
Why DOCS Fits Healthcare Innovation
Doximity reported fiscal 2026 revenue of $644.9 million, up 13% year over year, adjusted EBITDA of $357.8 million, and free cash flow of $317.5 million. Its network includes more than 85% of U.S. physicians, and management said it reached more than 800,000 active prescribers using workflow tools in Q4 fiscal 2026, with nearly half of those providers using clinical AI during the quarter.
Core 6- to 12-Month Catalysts
- AI workflow adoption: Doximity GPT, Scribe, PeerCheck, clinical search and related tools can increase provider engagement and strengthen the platform’s moat.
- Partnership ramp: New partnerships with Aledade and Photon are expected to bring Doximity’s Clinical AI Suite to thousands of independent practices and add in-workflow prescribing capabilities.
- Upcoming earnings proof points: Management guided fiscal Q1 2027 revenue to $151 million to $152 million and adjusted EBITDA to $68.5 million to $69.5 million. Beating or raising guidance could reset sentiment after a period of skepticism around growth.
- Free-cash-flow and buyback support: Doximity generated $317.5 million of free cash flow in fiscal 2026 and repurchased $431.7 million of common stock during the year, giving the stock a valuation support mechanism if cash generation holds.
Valuation and Balance Sheet
At the latest available market data used for this screen, DOCS traded near $20.30 with a market capitalization of about $4.0 billion. Against fiscal 2026 free cash flow of $317.5 million, that implies a high-single-digit free-cash-flow yield before adjusting for cash and marketable securities. Doximity also had approximately $219.2 million of cash and $529.4 million of marketable securities at March 31, 2026, versus total liabilities of about $172.9 million, creating a strong survivability profile.
Key Risks
- Pharma and health-system budget risk: If pharmaceutical marketing budgets remain cautious or clients delay spending commitments, revenue growth could stay below historical levels.
- AI monetization and competition risk: Clinical AI tools may drive engagement without translating into enough incremental revenue, and workflow, scribe and healthcare communication markets are competitive.
Bottom Line
DOCS is not the highest-beta healthcare AI story, but it offers one of the best combinations of thematic relevance, real user adoption, profitability, cash generation, and balance-sheet strength in the global small- and lower-mid-cap healthcare technology universe. For a six-month horizon, the setup depends on AI engagement continuing to improve and upcoming earnings showing that fiscal 2027 guidance is achievable or conservative.
Risk disclaimer: This content is for informational and research purposes only and is not personalized financial advice. Stocks can decline materially, and investors should do their own due diligence before making investment decisions.